The achieved results corroborated our previous findings that pyrrolo[3,4-d]pyridazinone derivatives can decrease TNF-α tissue levels in the inflamed tissues in various inflammation models in vivo [20,25] and those of Tan et al. [53], whose results show that some other derivatives of pyridazinone can decrease the TNF-α colonic level in DSS colitis model. The gene discussed is TNF; the disease is colitis.